Tharimmune Company Insiders
| THAR Stock | 1.90 0.01 0.53% |
Tharimmune's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Tharimmune suggests that virtually all insiders are extremely bullish. Tharimmune employs about 2 people. The company is managed by 2 executives with a total tenure of roughly 5 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2024-12-19 | Randy Milby | Acquired 4600 @ 2.12 | View | ||
| 2024-11-13 | Sireesh Appajosyula | Acquired 5000 @ 2.02 | View | ||
| 2024-10-08 | Sireesh Appajosyula | Acquired 5000 @ 1.93 | View |
Monitoring Tharimmune's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Tharimmune |
Tharimmune Management Team Effectiveness
The company has return on total asset (ROA) of (1.6508) % which means that it has lost $1.6508 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.5453) %, meaning that it created substantial loss on money invested by shareholders. Tharimmune's management efficiency ratios could be used to measure how well Tharimmune manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/17/2025, Return On Tangible Assets is likely to drop to -0.8. In addition to that, Return On Capital Employed is likely to grow to -1.13. At this time, Tharimmune's Total Assets are relatively stable compared to the past year. As of 02/17/2025, Net Tangible Assets is likely to grow to about 6.7 M, while Non Currrent Assets Other are likely to drop slightly above 437.3 K.As of 02/17/2025, Common Stock Shares Outstanding is likely to grow to about 105.1 K, though Net Loss is likely to grow to (7.2 M).
Tharimmune Workforce Comparison
Tharimmune is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 32,268. Tharimmune adds roughly 2.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Tharimmune Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tharimmune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tharimmune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Tharimmune insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Appajosyula Sireesh over a month ago Acquisition by Appajosyula Sireesh of 52875 shares of Tharimmune at 1.93 subject to Rule 16b-3 | ||
Milby Randy over a month ago Acquisition by Milby Randy of 4600 shares of Tharimmune at 2.12 subject to Rule 16b-3 | ||
Parikh Sanam over two months ago Insider Trading | ||
Bui Lynne A. over six months ago Acquisition by Bui Lynne A. of 2353 shares of Tharimmune at 2.925 subject to Rule 16b-3 | ||
Milby Randy over a year ago Purchase by Milby Randy of 29000 shares of Tharimmune | ||
Milby Randy over a year ago Purchase by Milby Randy of 10000 shares of Tharimmune |
Tharimmune Notable Stakeholders
A Tharimmune stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tharimmune often face trade-offs trying to please all of them. Tharimmune's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tharimmune's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Randy MBA | Chairman President | Profile | |
| Sireesh PharmD | COO Director | Profile |
About Tharimmune Management Performance
The success or failure of an entity such as Tharimmune often depends on how effective the management is. Tharimmune management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tharimmune management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tharimmune management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.77) | (0.80) | |
| Return On Capital Employed | (1.19) | (1.13) | |
| Return On Assets | (0.77) | (0.80) | |
| Return On Equity | (1.17) | (1.11) |
Tharimmune Workforce Analysis
Traditionally, organizations such as Tharimmune use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tharimmune within its industry.Tharimmune Manpower Efficiency
Return on Tharimmune Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 4.7M | |
| Net Loss Per Executive | 4.7M | |
| Working Capital Per Employee | 4.6M | |
| Working Capital Per Executive | 4.6M |
Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.